{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:02:57Z","timestamp":1790344977713,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The self-financing science and technology project of GuiGang","award":["GKG2200012"],"award-info":[{"award-number":["GKG2200012"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,14]]},"abstract":"<jats:p>Venous thromboembolic events (VTE) is a frequent complication in multiple myeloma (MM) patients, raising mortality. This study aims to use machine learning to identify VTE risk factors in MM, helping to pinpoint high-risk individuals for better clinical management and prognosis. A retrospective analysis was conducted on the basic information, laboratory test results, treatment plans, and thrombosis prevention measures of 428 newly diagnosed MM patients at our hospital from December 2018 to December 2022. We used logistic regression (LR), random forest, and gradient boosting machine (GBM) models to identify and assess the risk factors for VTE in patients with MM. Among 428 patients with MM, 48 cases (11.21%) had concomitant VTE, including 10 cases of deep vein thrombosis with pulmonary embolism, while the remaining 38 cases were solely deep vein thrombosis. The results of the multifactorial LR analysis indicate that C-reactive protein (CRP), fibrinogen, von Willebrand factor (vWF), factor VIII (FVIII), and treatment regimen immunomodulator in the patient\u2019s treatment regimen are independent factors influencing the risk of VTE in patients with MM. In the analysis of the random forest model, we found that CRP and fibrinogen are the most important factors for predicting the risk of VTE in patients with MM, with the highest Gini indices of 12.76 and 12.31, respectively. In addition, vWF, FVIII, age, platelet count, D-dimer, \u03b22 microglobulin, serum creatinine, and albumin were also considered key variables affecting the risk of VTE in MM patients. In the GBM model, the importance ranking of variables showed that FIB and CRP are the most important predictive factors, with influences of 36.84 and 28.56, respectively. In addition, other important variables include vWF, FVIII, age, albumin, neutrophils, \u03b22 microglobulin, and D-dimer. We found that CRP and fibrinogen were the most important risk factors in all 3 models, while vWF and FVIII were also confirmed as significant risk factors. The identification of these common risk factors provides a clear focus for clinical practice to more accurately identify high-risk groups for VTE among MM patients.<\/jats:p>","DOI":"10.1097\/md.0000000000041428","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:02:12Z","timestamp":1739818932000},"page":"e41428","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of risk factors for thromboembolic events in multiple myeloma patients using multiple machine learning models"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7821-687X","authenticated-orcid":false,"given":"Yi","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haimei","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoxin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Guigang City People\u2019s Hospital, Guigang, Guangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250217","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/ijc.34214","article-title":"Causal relationships between inflammatory factors and multiple myeloma: a bidirectional Mendelian randomization study.","volume":"151","author":"Wang","year":"2022","journal-title":"Int J Cancer"},{"key":"R2-20250217","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","article-title":"Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis.","volume":"9","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.3390\/cancers14246216","article-title":"Approach to contemporary risk assessment, prevention and management of thrombotic complications in multiple myeloma.","volume":"14","author":"Fotiou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R4-20250217","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma.","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"R5-20250217","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: every year a new standard.","volume":"37","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clml.2019.02.008","article-title":"When monoclonal gammopathy is of renal significance: a case study of crystalglobulinemiafrom Chicago multiple myeloma rounds.","volume":"19","author":"Gilmore","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"R8-20250217","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016.","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"R9-20250217","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20250217","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/cancers12010191","article-title":"Multiple myeloma and thrombosis: prophylaxis and risk prediction tools.","volume":"12","author":"Fotiou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R12-20250217","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11239-020-02191-8","article-title":"Using big data to retrospectively validate the COMPASS-CAT risk assessment model: considerations on methodology.","volume":"51","author":"Nikolakopoulos","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"R13-20250217","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00277-019-03860-2","article-title":"The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma.","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"key":"R14-20250217","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma.","volume":"17","author":"Li","year":"2019","journal-title":"Jo National Comprehensive Cancer Netw"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism.","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/rth2.12411","article-title":"Venous thromboembolism in multiple myeloma is associated with increased mortality.","volume":"4","author":"Schoen","year":"2020","journal-title":"Res Prac Thrombosis Haemostasis"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"E455","DOI":"10.1002\/ajh.24454","article-title":"Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs.","volume":"91","author":"Chalayer","year":"2016","journal-title":"Am J Hematol"},{"key":"R19-20250217","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/02683555231176911","article-title":"The role of D-dimer and fibrinogen testing in catheter-directed thrombolysis with urokinase for deep venous thrombosis.","volume":"38","author":"Liu","year":"2023","journal-title":"Phlebology"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.10454","article-title":"Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.","volume":"92","author":"Auwerda","year":"2007","journal-title":"Haematologica"},{"key":"R21-20250217","doi-asserted-by":"crossref","first-page":"1076029618823280","DOI":"10.1177\/1076029618823280","article-title":"Plasma Levels of vascular endothelial growth factor and selected hemostatic parameters in association with treatment response in multiple myeloma.","volume":"25","author":"Sokol","year":"2019","journal-title":"Clin App Thrombosis\/Hemostasis"},{"key":"R22-20250217","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.","volume":"1","author":"Minnema","year":"2003","journal-title":"J Thrombosis Haemostasis"},{"key":"R23-20250217","doi-asserted-by":"crossref","first-page":"37","DOI":"10.36290\/vnl.2019.009","article-title":"Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma.","volume":"65","author":"Kr\u00e1l","year":"2019","journal-title":"Vnitr Lek"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:02:20Z","timestamp":1739818940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041428","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}